net dbt
adjust ep line
report mix result better expect organ sale growth
lower expect ebitda takeaway press releas includ
organ sale growth beat forecast boost volum mix increas
north america improv sequenti organ growth vs
forecast driven volume/mix adjust ebitda miss
forecast addit one cost mostli north america held profit
expect ebitda segment broadli line expect
upsid canada off-set europ emea lower expect effect tax
rate made ebitda shortfal bring ep in-lin forecast key
question call rel previou commun ebitda full year
whether expens ebitda shortfal contain quarter whether
expect come well
buy rate base view better averag underli
fundament potenti valu ad strateg action expect oper
result continu improv balanc year
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
good
ni attribut nci
ni attribut
ni attribut common sharehold
rest world
rest world
rest world
price object base price-to-earnings multipl ep estim
multipl premium packag food group average believ
justifi higher peer ep growth near term due acceler cost
save balanc sheet de-lever potenti sale synergi enhanc strateg
potenti associ new manag team
given scope merger sever risk factor price
object consid scope complex integr potenti sale
continu declin given overal weak demand packag food beverag
north america initi debt level debt/ebitda constrain cash flow
leverag ratio come level fluctuat commod cost
bryan spillan herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
